ArticleJournal of radiation research2025
Impact of total neoadjuvant therapy regimens on radiation-induced lymphopenia in locally advanced rectal cancer: a retrospective analysis.
Article in Journal of radiation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The microbiota-lymphocyte protective axis (MLPA): a novel paradigm for overcoming radiation-induced lymphopenia (RIL) and potentiating the efficacy of tumor immuno-combination therapy.Cancer immunology, immunotherapy : CII · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Total neoadjuvant therapy (TNT) improves oncological outcomes in locally advanced rectal cancer (LARC); however, treatment-induced lymphopenia remains a concern. We analyzed 74 patients undergoing three TNT regimens: long-course chemoradiotherapy with consolidation chemotherapy (LCCRT-CNCT), short-course radiotherapy with CNCT (SCRT-CNCT), and induction chemotherapy with LCCRT (INCT-LCCRT). Severe radiation-induced lymphopenia (RIL, Grade ≥ 3) occurred in 48%, 24%, and 54%, respectively (P = 0.126). In the LCCRT-CNCT group, large bowel irradiation (V35 Gy > 46 cc) was significantly associated with severe RIL in univariable analysis but not in multivariable models (P = 0.227), and in an exploratory combined analysis of LCCRT-CNCT and INCT-LCCRT, this showed a trend (P = 0.093). Pre-TNT absolute lymphocyte count (ALC) was an independent predictor of RIL. Small bowel irradiation (V15 Gy > 104 cc) predicted severe lymphopenia during chemotherapy in the univariable analysis; but multivariable analysis suggested pre-TNT ALC as the main factor, showing a trend toward significance (P = 0.051). In the SCRT-CNCT group, pre-TNT ALC was the only significant factor for severe lymphopenia in both the RT and chemotherapy phases in univariable analysis. Severe RIL significantly prolonged lymphocyte recovery time (median, 283 vs. 76 days, P < 0.001), whereas immune recovery did not differ according to the TNT regimen. The median ALC at the last follow-up was 86% of the baseline value, indicating incomplete recovery. While pre-TNT ALC correlated with lymphopenia risk, minimizing bowel irradiation may help mitigate treatment-induced immunosuppression. Prospective studies are required to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.